Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.

Author: HuyckSusan, JiLinong, LauringBrett, LiuShu, LiuYanmei, MiaoHeng, MuYuting, PanSharon, QiuYanping, TerraSteven G, WangWei, XieYongli, YanPing, YangMing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, significantly improved glycemic control and reduced body weight and systolic blood pressure in Asian patients with type 2 diabetes mellitus (T2DM). It was generally well-tolerated, with results in the China subpopulation consistent with the overall population.
Paper Details　
Original Abstract of the Article :
AIM: Phase III, randomized, double-blind study evaluating the efficacy and safety of ertugliflozin in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, including evaluation in the China subpopulation. MATERIALS AND METHODS: A 26-week, double-blind study of 50...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379575/

データ提供：米国国立医学図書館（NLM）

Ertugliflozin: A Potential Oasis in the Desert of Type 2 Diabetes

Type 2 diabetes, a prevalent metabolic disorder, presents a significant challenge for healthcare professionals. This study evaluates the efficacy and safety of ertugliflozin, a novel antidiabetic agent, in Asian patients with type 2 diabetes inadequately controlled on metformin. The study's findings provide a promising avenue for improving glycemic control and reducing cardiovascular risk in these patients.

Ertugliflozin Shows Promise for Asian Patients

Ertugliflozin demonstrates a significant improvement in glycemic control in Asian patients with type 2 diabetes, leading to reductions in HbA1c, fasting plasma glucose, and body weight. The study also highlights the drug's favorable safety profile, with minimal side effects. These findings suggest that ertugliflozin may be a valuable addition to the therapeutic arsenal for managing type 2 diabetes in Asian populations.

Navigating the Desert of Diabetes Management

This research underscores the importance of culturally tailored diabetes management strategies. Like a camel navigating the diverse landscapes of the desert, clinicians must carefully consider the unique needs of different patient populations when selecting the optimal therapeutic approach for managing type 2 diabetes.

Dr. Camel's Conclusion

This study provides a valuable insight into the potential of ertugliflozin for improving glycemic control and reducing cardiovascular risk in Asian patients with type 2 diabetes. However, like a desert oasis, this therapy should be used judiciously under the guidance of a qualified healthcare professional.

Date :
  1. Date Completed 2020-05-29
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

30830724

DOI: Digital Object Identifier

PMC7379575

Related Literature

Article Analysis
・Side Effects of ertugliflozin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.